Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Raymond James & Associates

Raymond James & Associates raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 116,677 shares of the company’s stock after acquiring an additional 1,958 shares during the quarter. Raymond James & Associates owned 0.24% of Amphastar Pharmaceuticals worth $5,662,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in AMPH. TD Asset Management Inc increased its position in shares of Amphastar Pharmaceuticals by 67.4% in the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after buying an additional 680,976 shares in the last quarter. Millennium Management LLC grew its stake in Amphastar Pharmaceuticals by 84.6% in the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after acquiring an additional 338,653 shares during the last quarter. Epoch Investment Partners Inc. increased its holdings in Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after acquiring an additional 280,390 shares in the last quarter. Marshall Wace LLP acquired a new position in Amphastar Pharmaceuticals during the second quarter worth about $9,085,000. Finally, American Century Companies Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 19.7% in the second quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock valued at $29,616,000 after purchasing an additional 121,764 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Price Performance

NASDAQ AMPH opened at $50.53 on Friday. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The stock has a market capitalization of $2.47 billion, a P/E ratio of 17.57, a P/E/G ratio of 0.88 and a beta of 0.83. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. The business’s fifty day moving average is $48.17 and its two-hundred day moving average is $43.72.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The business had revenue of $182.39 million for the quarter, compared to the consensus estimate of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. On average, research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the sale, the director now directly owns 33,971 shares in the company, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the sale, the director now directly owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,101 shares of company stock valued at $1,069,350 in the last three months. Company insiders own 27.10% of the company’s stock.

Analyst Upgrades and Downgrades

AMPH has been the subject of several analyst reports. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, October 18th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.